You are here: Industry Insights > NICE

News List

UK NICE invites Roche to submit Cancer Drugs Fund proposal for atezolizumab pharmaceutical-technology
August 04, 2017
The UK National Institute for Health and Care Excellence (NICE) has invited Swiss healthcare company, Roche, to submit a Cancer Drugs Fund (CDF) proposal for its urothelial cancer drug, atezolizumab.
NICE turns down Tecentriq in bladder cancer but suggests Roche try again for some patients fiercepharma
August 03, 2017
Roche and England’s drug cost watchdog NICE are again in an arm-wrestling match, this time over the use of Roche’s cancer drug Tecentriq for metastatic urothelial cancer.
NICE draft guidance rejects Roche's Tecentriq for bladder cancer firstwordpharma
August 03, 2017
The National Institute for Health and Care Excellence issued draft guidance Wednesday recommending against NHS reimbursement of Roche's Tecentriq (atezolizumab) for treating locally advanced or metastatic urothelial carcinoma in adults after prior platinu
NICE nod for Allergan’s Truberzi for IBS-D pharmatimes
July 31, 2017
Cost regulators for NHS treatments in England and Wales are backing use of Allergan’s Truberzi to treat irritable bowel syndrome with diarrhoea (IBS-D) in patients who have not responded to or cannot take other treatments.-D
Roche hails 4 year NICE access deal for Gazyvaro pharmaphorum
July 27, 2017
NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the drug up to four years to prove its value to patients.
NICE recommends Roche’s blood cancer drug via Cancer Drugs Fund for rituximab refractory follicular firstwordpharma
July 27, 2017
Gazyvaro is one of the first in a series of innovative therapies that are expected to be considered by NICE this year via the new appraisal process for cancer medicines, and it could make a significant difference to patient outcomes across England.
NICE recommends Teva’s Cinqaero to treat severe eosinophilic asthma pharmaceutical-technology
July 24, 2017
The UK National Institute for Health and Care Excellence (NICE) has recommended Teva Pharmaceutical Industries’ Cinqaero (reslizumab) for the treatment of patients with severe eosinophilic asthma.
Teva’s Cinqaero to challenge Nucala after clearing NICE pharmaphorum
July 24, 2017
NICE has recommended Teva’s treatment for severe asthma Cinqaero, allowing it to challenge GSK’s rival Nucala.
NICE u-turn backs use of Teva’s asthma biologic pharmatimes
July 24, 2017
The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
NICE publishes new Parkinson’s clinical guidance europeanpharmaceuticalreview
July 24, 2017
Parkinson’s disease is one of the most common neurological conditions, affecting an estimated 130,000 people in the UK, with an annual incidence of around 15-20 per 100,000.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page